A rare cause of gastrointestinal bleeding in the post-transplant setting

Piyush Bawane, Mayank Jain, Mahadevan Balkrishnan, Ravi R, Joy Varghese, Jayanthi Venkataraman, Mukul Vij, Mohamed Rela

Gleneagles Global Health City, Chennai, India

Abstract
Post-transplant lymphoproliferative disorder (PTLD) is a life-threatening complication noted after solid organ transplantation and is frequently related to Epstein-Barr virus infection. The present case highlights an unusual presentation of PTLD – gastrointestinal bleeding – in the absence of systemic symptoms.

Key words: liver, bleeding, transplant recipients.

Address for correspondence
Mayank Jain, Gleneagles Global Health City, 439 Cheran Nagar, 600100 Chennai, India, phone: 917312365688, e-mail: mayank4670@rediffmail.com

Introduction
Post-transplant lymphoproliferative disorder (PTLD) is a life-threatening complication noted after solid organ transplantation and is frequently related to Epstein-Barr virus (EBV) infection [1]. The frequency varies from 1.4% in liver transplant recipients to 6.2% in lung transplant recipients [2]. The risk of lymphomas in renal transplant recipients is 11.8-fold higher than in a matched nontransplanted population. First-year mortality in renal and heart transplant patients with lymphoma is approximately 40% and 50%, respectively [3]. Post-transplant lymphoproliferative disorder is classified, based on the WHO classification, as early lesions, polymorphic, monomorphic and classical Hodgkin lymphoma type PTLD [4]. The majority of cases of PTLD are of recipient origin, though donor-derived lymphomas can occur [5]. Although most cases of PTLD are associated with EBV infection, EBV-negative lymphomas have been reported. These typically occur late, more than 1 year after transplantation. Epstein-Barr virus latent membrane protein 1 (LMP1) has been implicated in the transformation of B lymphocytes through a receptor in the tumor necrosis factor receptor family [5, 6]. Immunosuppression, particularly with cyclosporine, OKT3, antithymocyte globulin and tacrolimus, is associated with increased risk of PTLD [7-9]. The clinical symptoms noted are fever and lymphadenopathy. Extranodal involvement and central nervous system involvement are noted in two thirds and one third of patients respectively [10, 11]. Poor performance status, monomorphic disease, EBV-negative status of the recipient, late onset of disease, disease involving multiple sites, advanced age, stage, elevated lactate dehydrogenase (LDH), severe organ dysfunction, CNS disease and grafted organ involvement are associated with poor prognosis [12-15].

Case report
A 63-year-old male patient presented to the emergency department with a history of painless, black tarry stools for two days. He was a known diabetic and had undergone DDLT (deceased donor liver transplantation) for nonalcoholic steatohepatitis (NASH) in 2014. He was on oral hypoglycaemics, tacrolimus 1.5 mg/day and mycophenolate mofetil 1 g/day. Apart from pallor and a well-healed abdominal scar, no major abnormality was noted on physical examination. After initial stabilization, the patient was taken up for endoscopic evaluation. Esophagogastroduodenoscopy was normal. Colonoscopy with ileal intubation showed a large,
After confirmation of the diagnosis, the tacrolimus dose was reduced and everolimus was added. The patient was counseled regarding the disease and its prognosis. He was advised to undergo CT scans of the chest, brain and neck to determine the disease severity. However, the patient refused any further medical treatment and left the hospital against medical advice.

Discussion

There have been reports of endoscopic detection of PTLD lesions in the small intestine [16]. In a large series reported by Cruz et al., it was noted that patients with gastrointestinal PTLD were of late onset, often involved the lower gastrointestinal tract and were monoclonal in origin. In the author’s series, intestinal obstruction was the commonest indication for surgery; bleeding or perforation carried a worse prognosis [17].

Our patient was more than 60 years of age and three years after the transplant. He had been on tacrolimus since the transplant. He had no documented episodes of acute rejection. The patient and his donor were both EBV negative. He presented with melena and there was no history of systemic symptoms such as fever and no lymphadenopathy was noted. Computed tomography of the abdomen did not reveal any abdominal lymph nodes. On histopathology, he had pleomorphic PTLD as per the WHO classification.

Treatment strategies that could benefit such patients include decreasing cyclosporine or tacrolimus by 50% and discontinuing azathioprine or mycophenolate mofetil [18], use of antiviral agents in patients with early or polymorphic disease [19], chemotherapy with or without rituximab [20, 21] and hematopoietic transplantation in recurrent cases [22].
Preventive strategies are also being investigated to prevent PTLD. Vaccination against EBV may provide protection, particularly in EBV-naive pediatric patients. A vaccine directed against gp350, a viral membrane protein, is currently under trial [23]. Anti-viral prophylaxis in EBV negative recipients has also been tried with variable results [24, 25]. To conclude, the present case highlights an unusual presentation of PTLD in an EBV negative recipient. PTLD should be kept as a differential diagnosis for varied gastrointestinal manifestations such as obstruction, perforation and bleeding in solid organ transplant recipients. 

Disclosure

Authors report no conflict of interest.

References

1. Tanner JE, Alfierti C. The Epstein-Barr virus and post-transplant lymphoproliferative disease: interplay of immunosuppression, EBV, and the immune system in disease pathogenesis. Transpl Infect Dis 2001; 3: 60-69.
2. Walker RC, Paya CV, Marshall WF, et al. Pre-transplantation seronegative Epstein-Barr virus status is the primary risk factor for posttransplantation lymphoproliferative disorder in adult heart, lung, and other solid organ transplantations. J Heart Lung Transplant 1995; 14: 214-221.
3. Opelz G, Döhler B. Lymphomas after solid organ transplantation: a collaborative transplant study report. Am J Transplant 2004; 4: 222-230.
4. WHO Classification of posttransplant lymphoproliferative disorders. PathologyOutlines.com. Available at: http://www.pathologyoutlines.com/topic/lymphomanonBposttranswho.html (Accessed: 7 June 2017).
5. Weissmann DJ, Ferry JA, Harris NL, et al. Posttransplantation lymphoproliferative disorders in solid organ recipients are predominantly aggressive tumors of host origin. Am J Clin Pathol 1995; 103: 748-755.
6. Mosialos G, Birkenbach M, Yalamanchili R, et al. The Epstein-Barr virus transforming protein LMP1 engages signaling proteins for the tumor necrosis factor receptor family. Cell 1995; 80: 389-399.
7. Libertiny G, Watson CJ, Gray DW, et al. Rising incidence of post-transplant lymphoproliferative disease in kidney transplant recipients. Br J Surg 2001; 88: 1330-1334.
8. Bustami RT, Ojo AO, Wolfe RA, et al. Immunosuppression and the risk of post-transplant malignancy among cadaveric first kidney transplant recipients. Am J Transplant 2004; 4: 87-93.
9. Caillard S, Dharinandhara V, Agodoa L, et al. Posttransplant lymphoproliferative disorders after renal transplantation in the United States in era of modern immunosuppression. Transplantation 2005; 80: 1233-1243.
10. Boubenider S, Hiesse C, Goupy C, et al. Incidence and consequences of post-transplantation lymphoproliferative disorders. J Nephrol 1997; 10: 136-145.
11. Penn I, Porat G. Central nervous system lymphomas in organ allograft recipients. Transplantation 1995; 59: 240-244.
12. Ghobrial IM, Habermann TM, Maurer MJ, et al. Prognostic analysis for survival in adult solid organ transplant recipients with post-transplantation lymphoproliferative disorders. J Clin Oncol 2005; 23: 7574-7582.
13. Tsai DE, Hardy CL, Tomaszewski JE, et al. Reduction in immunosuppression as initial therapy for posttransplant lymphoproliferative disorder: analysis of prognostic variables and long-term follow-up of 42 adult patients. Transplantation 2001; 71: 1076-1088.
14. Choquet S, Mamzer BM, Hermine O, et al. Identification of prognostic factors in post-transplant lymphoproliferative disorders. Recent Results Cancer Res 2002; 159: 67-80.
15. Benkerrou M, Jais JP, Leblond V, et al. Anti-B-cell monoclonal antibody treatment of severe posttransplant B-lymphoproliferative disorder: prognostic factors and long-term outcome. Blood 1998; 92: 3137-3147.
16. Tawara S, Shinzaki S, Nishida T, et al. Post-transplant lymphoproliferative disorder of the ileum diagnosed by double-balloon enteroscopy. Endoscopy 2013; 45: E380-E381.
17. Cruz RJ Jr, Ramachandra S, Sasatomi E, et al. Surgical management of gastrointestinal posttransplant lymphoproliferative disorders in liver transplant recipients. Transplantation 2012; 94: 417-423.
18. Paya CV, Fung JJ, Nalesnik MA, et al. Epstein-Barr virus-induced post-transplant lymphoproliferative disorders. ASTS/ASTP EBV-PTLD Task Force and The Mayo Clinic Organized International Consensus Development Meeting. Transplantation 1999; 68: 1517-1525.
19. Starzl TE, Nalesnik MA, Porter KA, et al. Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy. Lancet 1984; 1: 583-587.
20. Fischer A, Blanche S, Le Bidon J, et al. Anti-B-cell monoclonal antibodies in the treatment of severe B-cell lymphoproliferative syndrome following bone marrow and organ transplantation. N Engl J Med 1991; 324: 1451-1456.
21. Milpied N, Vasseur B, Parquet N, et al. Humanized anti-CD20 monoclonal antibody (rituximab) in post transplant B-lymphoproliferative disorder: a retrospective analysis on 32 patients. Ann Oncol 2000; 11 (Suppl 1): 113-116.
22. Lee TC, Savoldo B, Rooney CM, et al. Quantitative EBV viral loads and immunosuppression alterations can decrease PTLD incidence in pediatric liver transplant recipients. Am J Transplant 2005; 5: 2222-2228.
23. Gu SY, Huang TM, Ruan L, et al. First EBV vaccine trial in humans using recombinant vaccinia virus expressing the major membrane antigen. Dev Biol Stand 1995; 84: 1517-1525.
24. Funch DP, Walker AM, Schneider G, et al. Ganciclovir and acyclovir reduce the risk of post-transplant lymphoproliferative disorder: prognostic factors in renal transplant recipients. Am J Transplant 2005; 5: 2894-2900.
25. McDermid SV, Jordan S, Kim GS, et al. Prevention and preemptive therapy of posttransplant lymphoproliferative disease in pediatric liver recipients. Transplantation 1998; 66: 1604-1611.